September marks Prostate Cancer Awareness Month, and a recent survey by The Ohio State University Comprehensive Cancer Center (OSUCCC) reveals that nearly 80% of people are unaware that early-stage prostate cancer frequently presents without any physical symptoms and is usually detected through a blood test.

According to the National Cancer Institute (NCI), prostate cancer impacts more than 300,000 adults annually in the U.S and predominantly affects men over 50. Fortunately, when identified at an early stage, it is highly treatable.

“It originates in the prostate gland and typically doesn’t cause noticeable symptoms in its initial stages, making regular screenings crucial,” stated Edmund Folefac, MD, a medical oncologist at OSUCCC – James. “Prostate cancer generally progresses slowly, and if detected early, it is very manageable.”

The survey by OSUCCC – James also found that over 59% of participants were unaware that sexual dysfunction could indicate prostate cancer, with partners often being the first to notice these changes and prompting their male companions to consult healthcare providers.

In a poll involving more than a thousand adults aged 18 and above, Black respondents were more likely to recognize less common prostate cancer symptoms, such as fatigue (33% of Black adults compared to 24% of white adults) and weight loss (30% of Black adults compared to 20% of white adults).

Nevertheless, Black respondents were less aware than other racial or ethnic groups that early-stage prostate cancer often exhibits no symptoms (12% of Black adults versus 21% of white adults).

“Knowing your family history is very important,” said Folefac, also a clinical associate professor at Ohio State College of Medicine. “If your father, brother or grandfather was diagnosed with prostate cancer, you have a higher risk of getting the disease and you should start screenings early and regularly.”

Current national guidelines suggest men should start getting screened for prostate cancer at age 50.

To learn more about cancer treatment and clinical trials at the OSUCCC – James, click here or call 1-800-293-5066.